Literature DB >> 23445369

Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound.

Marzia Galassi1, Massimo Iavarone, Sandro Rossi, Simona Bota, Sara Vavassori, Laura Rosa, Simona Leoni, Laura Venerandi, Sara Marinelli, Angelo Sangiovanni, Letizia Veronese, Mirella Fraquelli, Alessandro Granito, Rita Golfieri, Massimo Colombo, Luigi Bolondi, Fabio Piscaglia.   

Abstract

AIM: Primary aim was to validate the percentage of intrahepatic cholangiocarcinomas (ICC) which have a contrast vascular pattern at contrast enhanced ultrasound (CEUS) at risk of misdiagnosis with hepatocellular carcinoma (HCC) and, secondary aim, to verify if any characteristics in the CEUS pattern helps to identify ICC.
METHODS: All ICC on cirrhosis seen in three Italian centres (Bologna, Milan and Pavia) between 2003 and 2011, in which CEUS and at least another imaging technique (CT or MRI) had been performed, were retrospectively identified. Those patients with ICC size comparable to the early HCC stage (Milan criteria, considered as small ICC) were enrolled for this study. The enhancement pattern at CEUS was analysed and compared with CT or MRI.
RESULTS: A total of 25 small ICC made this study group. CEUS was at risk of misdiagnosis of ICC for HCC in a significantly higher number of cases than in CT (performed in 24 ICC) (52% vs. 4.2%, P = 0.009) and MRI (11 ICC) (52% vs. 9.1%, P = 0.02). A different contrast pattern among all techniques was found in 6 of 10 ICC lesions submitted to the three imaging methods. In the arterial phase, ICC lacked global hyperenhacement in approximately 50% of cases at CEUS and the degree of intensity of wash-out in the late phase was marked in 24% of nodules.
CONCLUSIONS: CEUS misdiagnosed as HCC a significantly higher number of ICC lesions in cirrhotic patients than CT and MRI. However, some CEUS contrast features can help suspect ICC, especially in some cases with inconclusive CT or MRI.
© 2013 John Wiley & Sons A/S.

Entities:  

Mesh:

Year:  2013        PMID: 23445369     DOI: 10.1111/liv.12124

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  34 in total

Review 1.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

2.  Distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma in patients with and without risks: the evaluation of the LR-M criteria of contrast-enhanced ultrasound liver imaging reporting and data system version 2017.

Authors:  Fei Li; Qing Li; Yubo Liu; Jing Han; Wei Zheng; Yini Huang; Xueyi Zheng; Longhui Cao; Jian-Hua Zhou
Journal:  Eur Radiol       Date:  2019-07-11       Impact factor: 5.315

Review 3.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

Review 4.  Contrast-enhanced ultrasound in liver cancer.

Authors:  Simona Leoni; Ilaria Serio; Anna Pecorelli; Sara Marinelli; Luigi Bolondi
Journal:  Hepat Oncol       Date:  2015-01-12

Review 5.  [Diagnostics and treatment of cholangiocellular carcinoma].

Authors:  L Zender; N P Malek
Journal:  Internist (Berl)       Date:  2016-12       Impact factor: 0.743

6.  Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma.

Authors:  Saleh A Alqahtani; Faisal M Sanai; Ashwaq Alolayan; Faisal Abaalkhail; Hamad Alsuhaibani; Mazen Hassanain; Waleed Alhazzani; Abdullah Alsuhaibani; Abdullah Algarni; Alejandro Forner; Richard S Finn; Waleed K Al-Hamoudi
Journal:  Saudi J Gastroenterol       Date:  2020-10       Impact factor: 2.485

Review 7.  Imaging Diagnosis of Hepatocellular Carcinoma: Recent Advances of Contrast-Enhanced Ultrasonography with SonoVue®.

Authors:  Veronica Salvatore; Alice Gianstefani; Giulia Negrini; Giulia Allegretti; Marzia Galassi; Fabio Piscaglia
Journal:  Liver Cancer       Date:  2015-12-18       Impact factor: 11.740

Review 8.  Cholangiocarcinoma.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Lancet       Date:  2014-02-26       Impact factor: 79.321

9.  Contrast-Enhanced Ultrasound for the Characterization of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

Authors:  Guang-Jian Liu; Wei Wang; Ming-De Lu; Xiao-Yan Xie; Hui-Xiong Xu; Zuo-Feng Xu; Li-Da Chen; Zhu Wang; Jin-Yu Liang; Yang Huang; Wei Li; Jin-Ya Liu
Journal:  Liver Cancer       Date:  2015-10-21       Impact factor: 11.740

10.  Potential diagnostic performance of contrast-enhanced ultrasound and tumor markers in differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and cholangiocarcinoma.

Authors:  Xiao-Wen Huang; Yang Huang; Li-da Chen; Zhu Wang; Zheng Yang; Jin-Ya Liu; Xiao-Yan Xie; Ming-De Lu; Shun-Li Shen; Wei Wang
Journal:  J Med Ultrason (2001)       Date:  2017-10-20       Impact factor: 1.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.